FDA Update: Sotagliflozin Approved For Broad HF Treatment
WEBJun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
SGLT2 inhibitor empagliflozin is shown to be safe and effective for ...
WEBSep 2, 2024 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction...
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
WEBJun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
KDIGO provided recommendations on SGLT2 inhibitors and …
WEBMay 12, 2023 · Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
Applications of SGLT2 inhibitors beyond glycaemic control
WEBApr 26, 2024 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of kidney disease progression in people with or without diabetes as well as the risk of acute kidney injury and...
SGLT2 Inhibitors Reduce Cardiovascular Risks Independent of GLP …
WEBJun 20, 2024 · Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and kidney outcomes in patients with type 2 diabetes with or without concomitant use of glucagon-like peptide-1...
FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and ... - Pfizer
WEBDec 22, 2017 · Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved STEGLATRO™ (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) tabl...
SGLT inhibitors: a serendipitous glycaemic tale - Nature
WEBNov 20, 2023 · SGLT2 present in the early proximal convoluted tubule of nephrons reabsorbs the majority of glucose from the glomerular filtrate, whereas SGLT1 reabsorbs the remaining glucose in the late...
SGLT2 inhibitors and GLP-1 receptor agonists: established and …
WEBSGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as glucose lowering therapies, with additional benefits of weight loss and blood pressure reduction.
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond …
WEBJul 14, 2020 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic therapies in patients with type 2 diabetes mellitus and are associated with improved glycaemic control as well...